Log In
BCIQ
Print this Print this
 

Adynovate, Adynovi (BAX 855)

Also known as: BAX-855

  Manage Alerts
Collapse Summary General Information
Company Baxalta Inc.
DescriptionPegylated form of recombinant Factor VIII
Molecular Target Factor VIII
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsTreat hemophilia A; Treat hemophilia A in pediatric patients
Regulatory Designation
PartnerNektar Therapeutics

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$32,000.0M

$12,639.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$32,000.0M

$12,639.9M

0

Get a free BioCentury trial today